Lupus & antiphospholipid syndrome
Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD)
Authors' conclusion
Anti-ANXA5 IgG autoantibody reactivity might represent a predictive biomarker for PAH associated with MCTD and SLE.
Study context
- Population
- Patients with CTD excluding SSc (SLE, MCTD, primary SS), French multicentre auto-HTAP study
- Participants
- 86 patients
- Exposure
- CTD patients with PAH vs without PAH
- PAH+n = 32
- PAH-n = 54reference
- Outcome
- Autoantibodies (AFA, AECA) discriminating for PAH associated with SLE, MCTD and primary SS, and their target antigens
Methodological detailsmulticentre, proteomics, 1D and 2D immunoblots, ELISA confirmation
- Multicentre
- Proteomics
- 1D and 2D immunoblots
- ELISA confirmation
Main finding
As reported in the abstract
Anti-ANXA5 IgG reactivity
PAH+ IgG recognised fibroblast protein spots not recognised by PAH- IgG, including Annexin A5 (ANXA5)
39
PAH+ IgG recognised endothelial cell protein spots not recognised by PAH- IgG
34
Observational data: associations, not effects.
Further findings
IgG anti-fibroblast (AFA) and AECA reactivity in 1D immunoblots, PAH+
- PAH+ with IgG AFA reactivity
- 56.2%
- PAH+ with IgG AECA reactivity
- 40.6%
Protein spots recognised by serum IgG pools in 2D immunoblots (fibroblasts / endothelial cells)
- SLE (n = 14), fibroblasts
- 273 ± 79
- MCTD (n = 10), fibroblasts
- 205 ± 77
- SS (n = 9), fibroblasts
- 109 ± 11
- Healthy controls, fibroblasts
- 109
- SLE, endothelial cells
- 189 ± 48
- MCTD, endothelial cells
- 146 ± 30
- SS, endothelial cells
- 88 ± 33
- Healthy controls, endothelial cells
- 190
Original publication
Anti-fibroblast and anti-endothelial cell autoantibodies in pulmonary arterial hypertension (PAH) in patients with connective tissue diseases (CTD). Rheumatology (Oxford). Published 7 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →